Shares in Scholar Rock have gone into overdrive after the biotech ... which is designed to work directly on the muscles in SMA, binding pro- and latent forms of myostatin to bolster muscle ...

Scholar Rock is a biopharmaceutical company that discovers ... Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and ...

Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, ...

CAMBRIDGE, Mass., January 17, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

The last time I wrote about Scholar Rock (NASDAQ:SRRK) it was with respect to a Seeking Alpha article entitled as "Scholar Rock: SMA Program Strides Forward With Positive Clinical Data".

In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other stocks. One of the strongest stock market anomalies is the momentum ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) has disclosed the presentation intended for the 43rd Annual J.P. Morgan Healthcare Conference in a recent filing with the U.S. Securities and ...

M.D., Ph.D., Chief Medical Officer of Scholar Rock. “With the strength of our Phase 3 data as the foundation of our submission, we look forward to continuing to work closely with the FDA through ...

In recent trading, shares of Scholar Rock Holding Corp (Symbol: SRRK) have crossed above the average analyst 12-month target price of $44.00, changing hands for $44.32/share. When a stock reaches ...